Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 2.15p 2.00p 2.30p 2.15p 2.15p 2.15p 304,426 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.0 -2.0 -0.5 - 9.91

Nuformix Share Discussion Threads

Showing 126 to 150 of 150 messages
Chat Pages: 6  5  4  3  2  1
DateSubjectAuthorDiscuss
11/1/2019
15:07
Not complaining though.only 3 small buys today and two of them were mine.cracking price once you have researched and seen how massive this can become gla ;-)
splatted
11/1/2019
15:02
A couple of sellers today don't seem to share our enthusiasm :-(
splatted
11/1/2019
12:06
agree completely. Keeping fingers crossed for news soon.
src33
11/1/2019
11:41
Very quiet here. Been buying the last few weeks. Very exciting and totally under the radar stock
splatted
07/12/2018
15:17
Plus looking to complete rest of world out licensing for NXP001 whilst completing upcoming milestones.
soupdragon55
07/12/2018
15:00
Summary of cash flow. From NXP001 Received £500k this quarter. Will receive another £500k Q1 2019 Then £2m in Q2 2019. Also suggesting new products on the way.
soupdragon55
07/12/2018
14:54
Good interview with Dan Gooding by IG on the below link. A lot more depth than the usual Vox Markets fluff. Https://youtu.be/rRccHplXSDY
soupdragon55
03/12/2018
07:21
Confirmation RNS.Nuformix PLC03 December 2018Nuformix plc("Nuformix" or the "Company")Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 ProgrammeData show Nuformix Investigational Candidates (NXP002) outperform current standard of careCambridge, UK, 3rd December 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis ('IPF') against standard of care[1].Multi-patient tissue studies were performed in partnership with Newcastle University, UK using a leading-edge human tissue trial model that closely replicates the clinical disease:-- Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions -- In addition, NXP002 demonstrated specific action measured against key inflammatory targets -- NXP002 out-performed current standard of care treatment, Esbriet (R) (pirfenidone) In partnership with the Newcastle University Fibrosis Research Group, UK, these results are the first of their kind to be published. Despite this being a challenging model of end-stage disease, the outcomes are considered highly positive and a portent for wider applications in other fibrotic lung conditions.Dr Dan Gooding, CEO, Nuformix plc, said: "Despite the advent of new treatments, life expectancy has not really changed for patients diagnosed with IPF. Few patients respond to current treatments and have to tolerate severe side effects that dramatically impact quality of life - severe vomiting on one therapy or severe diarrhoea on the other. This promising data gives us confidence in our ability to both inhibit fibrosis and attenuate inflammation in patients without these side effects."Newcastle University use a highly innovative new human tissue model, which has the potential to become the new gold standard for pre-clinical studies. These findings are important for IPF patients and show our NXP002 programme can play an important role in improving on current treatment options and extending both life and its quality."Nuformix will now seek to optimise delivery of a candidate within its NXP002 programme to maximise efficacy and tolerability using its patented novel drug forms before moving into patient studies.
soupdragon55
02/12/2018
21:40
Good spot src."The company takes old drugs cast off by major pharmaceutical companies, works its magic ('repurposes' the drug to use the industry term) and then finds a new use for them. In this case, GlaxoSmithKline dumped the drug years ago after a trial flopped.Nuformix is now developing the drug programme, called NXP002, to target lung fibrosis. In September, the company filed an extra patent for NXP002 so it can be used to treat other fibrotic conditions.I understand the results of the trial, carried out with the help of Newcastle University using lung tissue from multiple patients, are set to be positive.Stock watchers should keep an eye on the shares this week which could receive a nice booster from the news."
soupdragon55
02/12/2018
16:25
Nuformix tipped in the press today: https://www.thisismoney.co.uk/money/investing/article-6451947/STOCKWATCH-Drug-firm-Nuformix-formula-investor-tonic.html
src33
29/11/2018
16:14
Keeps trying but strength is sold into at present.
soupdragon55
27/11/2018
16:34
Didn't expect a 0 percent close. Oh well always tomorrow.
babbler
27/11/2018
12:42
Excellent article from the guys at Vox Markets hxxps://www.voxmarkets.co.uk/articles/nuformix-expands-licensing-agreement-after-studies-demonstrate-additional-commercial-applications-2d45664 Well worth a read P
porsche911sse
27/11/2018
11:12
'it is in discussion with multiple parties regarding rest of world rights, which are expected to deliver further upfront and milestone payments'. Curious why the markets have attributed no value to this statement - is there a large overhang of stock in the market?
mdchand
27/11/2018
09:16
Took a few here. Looks good.
theaviator
27/11/2018
08:41
150 and 100k shares buys taking up the freefloat.
babbler
27/11/2018
08:40
Would be more if they let you buy. Took me a good 6 minutes...
babbler
27/11/2018
08:32
The fact that NXP001 is showing potential for additional uses is key.
soupdragon55
27/11/2018
08:31
Certainly got the volume.
soupdragon55
27/11/2018
08:23
Can't get quote for 2k
babbler
27/11/2018
08:17
just added at 2.5 didnt expect that,markets!
ashtree2
27/11/2018
08:14
Thought it would rise more...
babbler
27/11/2018
08:09
And of course NXP002 to come.
soupdragon55
27/11/2018
07:46
Well done,first class
ashtree2
27/11/2018
07:22
27 November 2018Nuformix plc("Nuformix" or the "Company")Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care productReceives First Milestone Payment for NXP001Cambridge, UK, 27 November 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma ("NSB"), its Chinese licensing partner for NXP001, which is in development for cancer supportive care.Nuformix will be carrying out an additional pre-clinical study on NXP001 to further validate differentiated product opportunities. This will increase total milestone payments from NSB from GBP2.5 million to GBP3 million, following the addition of a second pre-clinical milestone of GBP500,000. NSB has now paid the Company the first milestone payment of GBP500,000, having achieved the first pre-clinical milestone for NXP001, as announced on 14 September 2018.Data from the recent NXP001 studies carried out by Nuformix demonstrate additional commercial applications beyond its initial intended use as a generic alternative to the marketed reference product. Nuformix plans to carry out an additional pre-clinical study on NXP001 for differentiated product forms in early Q1 2019. Data from the additional milestone studies will support regulatory submissions in China to facilitate market approval of multiple NXP001-derived products.The regulatory submission process is on-going in China with Nuformix supporting NSB, which has exclusive rights to NXP001 for marketing and distribution in China under its license agreement. Nuformix remains on track to commence its clinical studies for NXP001 in Q1 2019, with receipt of all milestone payments completed during Q2 2019.Commenting on the news, Dr Dan Gooding, CEO of Nuformix, said: "The expanded licensing agreement demonstrates NSB's commitment to the commercialisation of NXP001 and its understanding of the commercial opportunity in China. This is a large, untapped and growing market, which in demographic terms has one third of global cancer patients. The milestone payment received validates Nuformix's business model and its commitment to reinvest initial revenues back into R&D, avoiding further fund-raising at this stage whilst maximising the potential value of its cocrystal platform."The data also support Nuformix's business development activities for out-licensing the rest of world rights for NXP001. Nuformix confirms that, following these recent studies, it is in discussion with multiple parties regarding rest of world rights, which are expected to deliver further upfront and milestone payments for wider entry into the large and growing cancer supportive care market.Global cancer rates are soaring and whereas treatments increasingly extend life, side effects can severely limit and delay treatment. Effective supportive care ensures a patient's treatment remains on track. NXP001 has the potential to enable wider patient access to an under-utilised product within the growing oncology supportive care market. Over the last decade, China has emerged as the second largest global market and is on course to become the largest single market, having previously been outside the top 10.
soupdragon55
Chat Pages: 6  5  4  3  2  1
Your Recent History
LSE
NFX
Nuformix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190119 00:23:38